<?xml version="1.0" encoding="UTF-8"?>
<rss  xmlns:atom="http://www.w3.org/2005/Atom" 
      xmlns:media="http://search.yahoo.com/mrss/" 
      xmlns:content="http://purl.org/rss/1.0/modules/content/" 
      xmlns:dc="http://purl.org/dc/elements/1.1/" 
      version="2.0">
<channel>
<title>CHIRAL Bangladesh</title>
<link>https://chiralbd.github.io/news/</link>
<atom:link href="https://chiralbd.github.io/news/index.xml" rel="self" type="application/rss+xml"/>
<description>Announcements, publications and programme news from CHIRAL Bangladesh.</description>
<generator>quarto-1.10.18</generator>
<lastBuildDate>Fri, 04 Sep 2026 00:00:00 GMT</lastBuildDate>
<item>
  <title>Single-cell and network pharmacology study presented at IEEE BECITHCON 2026</title>
  <link>https://chiralbd.github.io/posts/becithcon-2026-ovarian-cancer/</link>
  <description><![CDATA[ 





<p><strong><a href="https://www.linkedin.com/in/mshahariar/">Musab Shahriar</a></strong>, Group Leader for In Silico Drug Discovery at CHIRAL Bangladesh, presented our collaborative study at <strong>IEEE BECITHCON 2026</strong> — the IEEE International Conference on Biomedical Engineering, Computer and Information Technology for Health.</p>
<blockquote class="blockquote">
<p><strong>Single-Cell Transcriptomic and Network Pharmacology Insights into the Therapeutic Potential of <em>Withania somnifera</em>-Derived Phytochemicals Against Cisplatin-Resistant Ovarian Cancer</strong></p>
</blockquote>
<p>Cisplatin remains the backbone of treatment for high-grade ovarian carcinoma, and relapse after resistance emerges is what most often decides the outcome. Resistance is not a property of the tumour as a whole but of particular cell states within it, which is why the study starts at single-cell resolution rather than with bulk expression.</p>
<section id="what-the-study-does" class="level3">
<h3 class="anchored" data-anchor-id="what-the-study-does">What the study does</h3>
<p>The work joins two analyses that are usually run apart. Single-cell RNA sequencing of ovarian cancer cohorts is used to resolve the cell states present in resistant tumours and the transcriptional programmes that separate them from sensitive ones, yielding a set of resistance-associated targets grounded in the cells that actually carry the phenotype.</p>
<p>Those targets then become the anchor for a network pharmacology screen of bioactive phytochemicals from <em>Withania somnifera</em> (ashwagandha), narrowed by molecular docking and structural dynamics to compounds with plausible binding to resistance-associated signalling. The result is a set of compound–target hypotheses for natural-product adjuvants, each traceable back to the cell population that motivated it — computational evidence to be tested, not a therapy.</p>
</section>
<section id="the-team" class="level3">
<h3 class="anchored" data-anchor-id="the-team">The team</h3>
<p>The work was carried out in the Big Bioinformatics Lab, part of the centre’s computational biology division. Congratulations to the full team:</p>
<ul>
<li><strong>Sheikh Naem Islam Abhi</strong></li>
<li><strong><a href="https://www.linkedin.com/in/mshahariar/">Musab Shahriar</a></strong> — presenter, Group Leader, In Silico Drug Discovery</li>
<li><strong>Lamia Hasan Joarder Barsha</strong></li>
<li><strong>Mst. Afsana Meme</strong></li>
<li><strong>Md. Jubayer Hossain</strong> — supervisor and founder</li>
</ul>
<p><a href="../../news/" class="c-btn c-btn--dark">All news &amp; announcements</a> <a href="../../groups/combio/" class="c-btn c-btn--line">Explore computational biology</a></p>


</section>

 ]]></description>
  <category>Conference</category>
  <category>Computational Biology</category>
  <category>Drug Discovery</category>
  <guid>https://chiralbd.github.io/posts/becithcon-2026-ovarian-cancer/</guid>
  <pubDate>Fri, 04 Sep 2026 00:00:00 GMT</pubDate>
</item>
<item>
  <title>Pan-cancer study of CCT5 published in Scientific Reports</title>
  <link>https://chiralbd.github.io/posts/cct5-pan-cancer-2025/</link>
  <description><![CDATA[ 





<p>Our pan-cancer analysis of the chaperonin subunit <strong>CCT5</strong> has been published in <em>Scientific Reports</em>.</p>
<p>The study examines CCT5 across 33 tumour types, covering gene and protein expression, DNA methylation, genetic alteration, immune cell infiltration, correlation with tumour mutational burden and microsatellite instability, drug sensitivity, and prognostic significance. CCT5 was overexpressed in most tumours and associated with poorer overall and disease-free survival in several of them; reduced promoter and N-shore methylation points to an epigenetic component, and amplification was the most common alteration observed.</p>
<p>The work was led by undergraduate researchers working through the centre’s supervision programme, from the initial question to the submitted manuscript.</p>
<p><a href="https://doi.org/10.1038/s41598-025-88339-z" class="c-btn c-btn--dark">Read the paper</a> <a href="../../publications/" class="c-btn c-btn--line">All publications</a></p>



 ]]></description>
  <category>Publication</category>
  <category>Computational Biology</category>
  <guid>https://chiralbd.github.io/posts/cct5-pan-cancer-2025/</guid>
  <pubDate>Wed, 15 Jan 2025 00:00:00 GMT</pubDate>
</item>
<item>
  <title>Junior researcher intake is open</title>
  <link>https://chiralbd.github.io/posts/junior-researcher-intake/</link>
  <description><![CDATA[ 





<p>We are accepting applications for the junior researcher track from university students in their first, second and third years.</p>
<p>The track is aimed at students who want to do research rather than read about it. Accepted applicants join one of our four groups, work under one-to-one supervision on an active project, and are expected to carry that project through to a manuscript. There is no fee, and there is no stipend.</p>
<p><strong>No prior programming experience is required.</strong> Foundational training in Linux, R and Python is provided through the centre’s <a href="../../training/">training programmes</a>. What we do ask for is consistency — the projects run over months, not weeks.</p>
<p>Students from life sciences, computer science, medicine, public health, pharmacy, statistics, geography and environmental science are all a fit.</p>
<p><a href="../../opportunities/" class="c-btn c-btn--dark">How to apply</a> <a href="../../research/" class="c-btn c-btn--line">Browse the groups</a></p>



 ]]></description>
  <category>Recruitment</category>
  <category>Training</category>
  <guid>https://chiralbd.github.io/posts/junior-researcher-intake/</guid>
  <pubDate>Mon, 06 Jan 2025 00:00:00 GMT</pubDate>
</item>
</channel>
</rss>
